Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Deloitte
Accenture
Merck
US Department of Justice
Dow
Harvard Business School
Julphar
Daiichi Sankyo

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,807,135

« Back to Dashboard

Which drugs does patent 7,807,135 protect, and when does it expire?

Patent 7,807,135 protects NEURACEQ and is included in one NDA.

This patent has thirty patent family members in twenty-five countries.
Summary for Patent: 7,807,135
Title:Stilbene derivatives and their use for binding and imaging amyloid plaques
Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Inventor(s): Kung; Hank F. (Wynnewood, PA), Kung; Mei-Ping (Wynnewood, PA), Zhuang; Zhi-Ping (Lansdale, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:11/305,333
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,807,135

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Piramal Imaging NEURACEQ florbetaben f-18 SOLUTION;INTRAVENOUS 204677-001 Mar 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,807,135

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,858,072 Stilbene derivatives and their use for binding and imaging amyloid plaques ➤ Sign Up
8,465,726 Stilbene derivatives and their use for binding and imaging amyloid plaques ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Citi
Covington
Merck
Daiichi Sankyo
AstraZeneca
Teva
Boehringer Ingelheim
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.